TMAO reductase, a biomarker for gut permeability defect induced inflammation, in mouse model of chronic kidney disease and dextran sulfate solution-induced mucositis | Zendy

Sompong Boonhai | Zendy; Kanthika Bootdee | Zendy; Wilasinee Saisorn | Zendy; Kullaya Takkavatakarn | Zendy; Patita Sitticharoenchai | Zendy; Somkanya Tungsanga | Zendy; Khajohn Tiranathanagul | Zendy; Asada Leelahavanichkul | Zendy

Open Access

TMAO reductase, a biomarker for gut permeability defect induced inflammation, in mouse model of chronic kidney disease and dextran sulfate solution-induced mucositis

Author(s) -

Sompong Boonhai,

Kanthika Bootdee,

Wilasinee Saisorn,

Kullaya Takkavatakarn,

Patita Sitticharoenchai,

Somkanya Tungsanga,

Khajohn Tiranathanagul,

Asada Leelahavanichkul

Publication year - 2021

Publication title -

asian pacific journal of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.405

H-Index - 33

ISSN - 0125-877X

DOI - 10.12932/ap-100321-1084

Subject(s) - kidney disease , inflammatory bowel disease , reductase , medicine , endocrinology , chemistry , biochemistry , disease , enzyme

The excretion of trimethylamine N-oxide (TMAO) (uremic toxin) into the intestine might be enhanced, due to the limited renal elimination in chronic kidney disease (CKD), possibly induced TMAO reductase (a TMAO-neutralizing enzyme) in gut bacteria. Detection of TMAO reductase in serum could be used as a biomarker of gut permeability defect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research